Letter re: Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study

被引：0
|
作者：
Hyon, Stephanie S. [1 ]
Elsawwah, Jana K. [1 ]
Harris, Maia A. [1 ]
Nemeth, Zoltan H. [2 ]
机构：
[1] Morristown Med Ctr, Dept Surg, Morristown, NJ USA
[2] Columbia Univ, Dept Anesthesiol, New York, NY 10027 USA
来源：
AMERICAN SURGEON | 2024年
关键词：
D O I：
10.1177/00031348241275721
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study
    Hammersting, Christoph
    Omran, Heyder
    Tripp, Christian
    Poetzsch, Bernd
    [J]. THROMBOSIS AND HAEMOSTASIS, 2009, 101 (02) : 325 - 332
  • [32] Anti-factor XA levels in critically ill trauma patients treated for venous thromboembolism with enoxaparin.
    Sing, R
    Barrett, MC
    Huynh, T
    Miles, W
    Jacobs, D
    Thomason, M
    Rutherford, EJ
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (12) : A170 - A170
  • [33] Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity
    Freeman, Andrew
    Horner, Tuesdy
    Pendleton, Robert C.
    Rondina, Matthew T.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 (07) : 740 - 743
  • [34] Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
    Wagner, Jonas
    Wruck, Henrike
    Lautenbach, Anne
    von Kroge, Philipp
    Wolter, Stefan
    Mann, Oliver
    Izbicki, Jakob
    Dupree, Anna
    [J]. OBESITY SURGERY, 2022, 32 (03) : 861 - 867
  • [35] Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
    Jonas Wagner
    Henrike Wruck
    Anne Lautenbach
    Philipp von Kroge
    Stefan Wolter
    Oliver Mann
    Jakob Izbicki
    Anna Duprée
    [J]. Obesity Surgery, 2022, 32 : 861 - 867
  • [36] Anti-factor Xa profiles in cardiac patients receiving enoxaparin therapy.
    Tse, ME
    Mak, M
    Mitani, GH
    Pickens, P
    Beringer, PM
    Tesoro, JT
    Sarma, R
    Louie, S
    [J]. PHARMACOTHERAPY, 2005, 25 (10): : 1437 - 1437
  • [37] ANTI-FACTOR XA ACTIVITY PROPHYLACTIC LEVELS IN LOW-BODY WEIGHT SURGICAL PATIENTS RECEIVING ENOXAPARIN 30 MG DAILY FOR VTE PREVENTION
    Hakeam, Hakeam
    Alwaibah, Reem
    Alshannan, Madhawi
    Shalhoub, Munirah
    [J]. CHEST, 2019, 156 (04) : 370A - 370A
  • [38] Pilot study examining anti-factor Xa levels for heparin monitoring and outcomes in patients with cerebral venous thrombosis
    Pirahanchi, Yasaman
    Salottolo, Kristin
    Burrell, Christian
    Tang, Xu
    Bar-Or, David
    Bartt, Russell
    [J]. FRONTIERS IN MEDICINE, 2024, 11
  • [39] Prophylactic Enoxaparin Adjusted by Anti-Factor Xa Peak Levels Compared with Recommended Thromboprophylaxis and Rates of Clinically Evident Venous Thromboembolism in Surgical Oncology Patients
    Kramme, Katherine
    Sarraf, Paya
    Munene, Gitonga
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 230 (03) : 314 - 321
  • [40] ACHIEVEMENT OF PROPHYLACTIC ANTI-XA LEVELS IN TRAUMA PATIENTS RECEIVING ENOXAPARIN
    Meadows, Evan
    Partlow, Karen
    Rubertus, Matthew
    Quick, Valerie
    Davis, John
    Flannagan, Molly
    Griffin, Mary Lewis
    [J]. CRITICAL CARE MEDICINE, 2024, 52
12345